Researchers have examined the incidence of myocarditis after mRNA COVID-19 vaccine immunization.
Researchers from NIAID and their academic partners found that while virus neutralization from antibodies from 15 persons who had received the Moderna COVID-19 vaccine and 10 persons who had received the Pfizer–BioNTech vaccine were reduced the antibodies retained 79% of activity against the B.1.617.1 (India) variant and 96% of activity against the B.1.617.2 (India, Delta) variant.
A meta-analysis, by the World Health Organization, of 27 trials involving 10,930 patients, evaluated IL-6 inhibitors in the treatment of COVID-19. At 28-days the mortality risk in tocilizumab or sarilumab patients was 22% compared to 25% with usual care or placebo. The mortality benefit was maintained in patients receiving corticosteroids (21% vs 25%). The data supporting tocilizumab was more robust than sarilumab due to the larger patient population and the trials being conducted later in the pandemic, when use of corticosteroids became more common. There was not enough data (one trial) to estimate the effect of using siltuximab. Based on the data, the WHO now recommends that either tocilizumab or sarilumab be added to corticosteroids for the treatment of severe or critical COVID-19 infections.
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker